Baseline characteristics
| Characteristic . | Arm A enoxaparin (n = 8) . | Arm B enoxaparin + rosuvastatin (n = 7) . | Arm C Standard of care (enoxaparin) (n = 9) . | Total cohort (N = 24) . |
|---|---|---|---|---|
| Age, median (IQR), y | 61 (54-71) | 56 (54-59) | 63 (59-71) | 60 (54-72) |
| Female, n (%) | 8 (100) | 7 (100) | 9 (100) | 24 (100) |
| Race, n (%) | ||||
| White | 7 (88) | 4 (57.1) | 8 (89) | 19 (79) |
| Black | 1 (13) | 0 (0) | 0 (0) | 1 (4) |
| Other | 0 (0) | 3 (42.9) | 1 (11) | 4 (17) |
| Ethnicity, n (%) | ||||
| Non-Hispanic | 6 (75) | 3 (42.9) | 8 (89) | 17 (71) |
| Unknown | 2 (25) | 4 (57.1) | 1 (11) | 7 (29) |
| Previous systemic therapy, n (%) | 2 (25) | 3 (42.9) | 4 (44) | 9 (38) |
| ECOG PS, n (%) | ||||
| 1 | 6 (75) | 7 (100) | 8 (89) | 21 (88) |
| 2 | 2 (25) | 0 (0) | 1 (11) | 3 (12) |
| Cancer stage, n (%) | ||||
| I | 1 (13) | 0 (0) | 1 (11) | 2 (8) |
| II | 1 (13) | 3 (43) | 0 (0) | 4 (17) |
| III | 5 (63) | 3 (43) | 8 (89) | 16 (67) |
| IV | 1 (13) | 1 (14) | 0 (0) | 2 (8) |
| Comorbidity, n (%) | ||||
| Hypertension | 3 (38) | 1 (14) | 3 (33.3) | 7 (29) |
| Hyperlipidemia | 1 (13) | 1 (14) | 3 (33.3) | 5 (21) |
| Diabetes | 0 (0) | 1 (14) | 1 (11) | 2 (8) |
| Myocardial infarction | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Chronic kidney disease | 1 (13) | 0 (0) | 0 (0) | 1 (4) |
| Liver disease | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| COPD | 0 (0) | 1 (14) | 0 (0) | 1 (4.2) |
| Baseline laboratory parameters, mean (SD) | ||||
| White blood count (x 103/uL) | 7.3 (3.1) | 6.3 (1.3) | 9.8 (2.8) | 7.9 (2.9) |
| Hemoglobin (g/dL) | 9.7 (0.9) | 9.7 (1.7) | 9.5 (1.9) | 9.5 (1.6) |
| Platelet count (x 109/uL) | 340 (250) | 240 (95) | 280 (150) | 290 (170) |
| Creatinine (mg/dL) | 0.65 (0.11) | 0.60 (0.10) | 0.99 (1.1) | 0.77 (0.69) |
| PT (s) | 12 (1.4) | 12 (1.8) | 12 (1.7) | 12 (1.6) |
| APTT (s) | 29 (4.9) | 29 (4.6) | 29 (3.1) | 29 (4.2) |
| Total bilirubin (mg/dL) | 0.48 (0.22) | 0.40 (0.13) | 0.37 (0.21) | 0.41 (0.19) |
| AST (U/L) | 29 (6.8) | 32 (11) | 41 (30) | 36 (21) |
| ALT (U/L) | 22 (11) | 25 (15) | 32 (22) | 28 (18) |
| ALP (U/L) | 180 (110) | 89 (63) | 98 (55) | 120 (79) |
| Characteristic . | Arm A enoxaparin (n = 8) . | Arm B enoxaparin + rosuvastatin (n = 7) . | Arm C Standard of care (enoxaparin) (n = 9) . | Total cohort (N = 24) . |
|---|---|---|---|---|
| Age, median (IQR), y | 61 (54-71) | 56 (54-59) | 63 (59-71) | 60 (54-72) |
| Female, n (%) | 8 (100) | 7 (100) | 9 (100) | 24 (100) |
| Race, n (%) | ||||
| White | 7 (88) | 4 (57.1) | 8 (89) | 19 (79) |
| Black | 1 (13) | 0 (0) | 0 (0) | 1 (4) |
| Other | 0 (0) | 3 (42.9) | 1 (11) | 4 (17) |
| Ethnicity, n (%) | ||||
| Non-Hispanic | 6 (75) | 3 (42.9) | 8 (89) | 17 (71) |
| Unknown | 2 (25) | 4 (57.1) | 1 (11) | 7 (29) |
| Previous systemic therapy, n (%) | 2 (25) | 3 (42.9) | 4 (44) | 9 (38) |
| ECOG PS, n (%) | ||||
| 1 | 6 (75) | 7 (100) | 8 (89) | 21 (88) |
| 2 | 2 (25) | 0 (0) | 1 (11) | 3 (12) |
| Cancer stage, n (%) | ||||
| I | 1 (13) | 0 (0) | 1 (11) | 2 (8) |
| II | 1 (13) | 3 (43) | 0 (0) | 4 (17) |
| III | 5 (63) | 3 (43) | 8 (89) | 16 (67) |
| IV | 1 (13) | 1 (14) | 0 (0) | 2 (8) |
| Comorbidity, n (%) | ||||
| Hypertension | 3 (38) | 1 (14) | 3 (33.3) | 7 (29) |
| Hyperlipidemia | 1 (13) | 1 (14) | 3 (33.3) | 5 (21) |
| Diabetes | 0 (0) | 1 (14) | 1 (11) | 2 (8) |
| Myocardial infarction | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Chronic kidney disease | 1 (13) | 0 (0) | 0 (0) | 1 (4) |
| Liver disease | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| COPD | 0 (0) | 1 (14) | 0 (0) | 1 (4.2) |
| Baseline laboratory parameters, mean (SD) | ||||
| White blood count (x 103/uL) | 7.3 (3.1) | 6.3 (1.3) | 9.8 (2.8) | 7.9 (2.9) |
| Hemoglobin (g/dL) | 9.7 (0.9) | 9.7 (1.7) | 9.5 (1.9) | 9.5 (1.6) |
| Platelet count (x 109/uL) | 340 (250) | 240 (95) | 280 (150) | 290 (170) |
| Creatinine (mg/dL) | 0.65 (0.11) | 0.60 (0.10) | 0.99 (1.1) | 0.77 (0.69) |
| PT (s) | 12 (1.4) | 12 (1.8) | 12 (1.7) | 12 (1.6) |
| APTT (s) | 29 (4.9) | 29 (4.6) | 29 (3.1) | 29 (4.2) |
| Total bilirubin (mg/dL) | 0.48 (0.22) | 0.40 (0.13) | 0.37 (0.21) | 0.41 (0.19) |
| AST (U/L) | 29 (6.8) | 32 (11) | 41 (30) | 36 (21) |
| ALT (U/L) | 22 (11) | 25 (15) | 32 (22) | 28 (18) |
| ALP (U/L) | 180 (110) | 89 (63) | 98 (55) | 120 (79) |
ALP, alkaline phosphatase; ALT, alanine aminotransferase; APTT, activated partial prothrombin time; AST, aspartate aminotransferase; COPD, chronic obstructive pulmonary disease; ECOG PS, Eastern Cooperative Oncology Group performance status; IQR, interquartile range; PT, prothrombin time; SD, standard deviation.